Verve names sec­ond PC­SK9 can­di­date; Ex­sci­en­tia picks an­oth­er AI-cre­at­ed mol­e­cule for clin­ic

Boston-based Verve Ther­a­peu­tics has un­veiled its sec­ond PC­SK9-tar­get­ing pro­gram.

The biotech an­nounced the can­di­date, dubbed Verve-102, as part of its wider third-quar­ter fi­nan­cial re­sults. Verve’s sec­ond PC­SK9-tar­get­ing can­di­date is an in vi­vo drug that us­es base edit­ing and is de­liv­ered through the com­pa­ny’s own tech­nol­o­gy known as GalNAc-LNP.

The biotech start­ed the reg­u­la­to­ry sub­mis­sion for the pro­gram ear­li­er this year and plans to start a Phase Ib tri­al to treat pa­tients with the ge­net­ic dis­or­der het­erozy­gous fa­mil­ial hy­per­c­ho­les­terolemia, or HeFH.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER